Sunday, June 1, 2025

Latest

Cognetivity Neurosciences Sees Former UK Health Minister Appointed To Advisory Board

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has added a former UK Health Minister to its advisory board. The appointment will see Lord O’Shaughnessy to the firms advisory board, effective immediately.

A member of the UK House of Lords, which is an upper house of the parliament within the United Kingdom, O’Shaughnessy comes highly experienced in the field of healthcare. Previously, he served as parliamentary under-secretary of state at the Department of Health, while also serving as the lead for the Medicines and Healthcare products Regulatory Agency, or MHRA.

Outside of his involvement in healthcare, James O’Shaughnessy has also served as a director of polcy to Prime Minister David Cameron and is currently a visiting professor for the Institute of Global Health Innovation at Imperial College London. Within healthcare, he currently serves as an advisor or director at a number of firms including Health Data Research UK, Healthy.io, Push Doctor, Bain & Company, and a number of healthcare related ventures.

“There’s no doubt that the future of healthcare looks increasingly digital – there are enormous improvements in patient outcomes to be made through the use of innovative technology. I greatly look forward to working with the team to ensure Cognetivity’s technology is able to improve the lives of as many people as possible.”

Lord O’Shaughnessy

Cognetivity Neurosciences last traded at $0.58 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Cognetivity Partners With UK National Health Service For New Remote Brain Health Clinic

Cognetivity Neuroscience (CSE: CGN) this morning indicated that it continues to see adoption of its...

Wednesday, July 14, 2021, 09:25:00 AM

Cognetivity Neurosciences Sees Granting Of FDA Clearance For Cognitive Assessment Tool

Cognetivity Neurosciences (CSE: CGN) has reached a major achievement. The company has been granted FDA...

Wednesday, October 20, 2021, 09:22:23 AM

Cognetivity Looks To Raise $3.0 Million To Fund US Expansion

Cognetivity Neurosciences (CSE: CGN) is looking to close out the year with a capital raise....

Thursday, December 16, 2021, 07:32:30 AM

Cognetivity Signs Commercial Agreement With Emirates Health Services Of UAE

Cognetivity Neurosciences (CSE: CGN) has entered the mainstream. The company this morning announced that it...

Tuesday, February 1, 2022, 08:48:42 AM

Cognetivity Reaches First Commercial Agreement In Middle East

Cognetivity Neurosciences (CSE: CGN) has seen the deployment of its technology to a new region...

Wednesday, September 22, 2021, 09:41:33 AM